The US FDA approves an in vivo CRISPR-based gene editing therapy for common cardiovascular disease before 2030

Question

Six frontier AI models put this at 16% by 5 Oct 2031. Full reasoning from every model.

WillHappen.ai · Accepted Answer

16% — the median of 6 frontier models, resolving by 2031-10-05.

Answer

Gemini (Google): 28% — Clinical trial timelines and FDA risk tolerance for permanent edits in non-fatal broad indications make a pre-2030 clearance tight. Verve's lead PCSK9 candidate VERVE-102 is only in early Phase 1b/2; Phase 3 outcome trials require thousands of patients and 3+ years. The FDA demands multi-year safety registries for permanent off-target liver edits before clearing healthy, broad populations. Accelerated approval via surrogate LDL-C reduction is the only plausible path, but safety holds could easily push resolution past 2029.

Answer

Claude (Anthropic): 12% — Hinges on Verve Therapeutics-style PCSK9/LDL in vivo editing completing pivotal trials and FDA review by 2030. Verve's VERVE-101/102 programs are only in early-mid stage trials as of 2025-2026, pivotal data unlikely before 2028-2029. FDA approval typically takes 1-2 years after pivotal trial completion plus BLA review, leaving a tight window to 2030. First-ever in vivo CRISPR approval (Casgevy was ex vivo) for a common disease like cardiovascular disease sets a high bar with no precedent yet.

Answer

GPT (OpenAI): 18% — The key hurdle is proving durable benefit and acceptable off-target safety in large, long cardiovascular trials. FDA has cleared in vivo CRISPR studies, but no such product is yet approved for a prevalent cardiovascular indication. Sponsors must complete pivotal outcomes or validated-surrogate trials, then submit and clear a BLA before 2030. The odds rise sharply if an LDL-targeting editor shows Phase 3-grade safety and durable lowering by 2028.

Answer

Grok (xAI): 18% — Verve-class PCSK9 editors must finish pivotal trials and FDA review by end-2029. Lilly/Verve VERVE-102 is still early-stage in 2026; a 2–3 yr Phase 3 plus 10-month BLA leaves almost no slack before 2030. No in-vivo CRISPR has yet been approved even for rare disease; the safety bar for a common CVD indication is higher still. A clean Phase 2 readout and immediate Phase 3 start in 2027 would be the single event that lifts this above 30.

Answer

DeepSeek (DeepSeek): 12% — This hinges on whether any in vivo CRISPR cardiovascular program reaches a pivotal readout and FDA filing within roughly five years. No in vivo CRISPR therapy for common cardiovascular disease is currently in pivotal trials; most candidates (e.g., Verve, Intellia) target rare conditions or are… FDA approval requires a large cardiovascular outcomes trial, typically 3-5 years, plus a filing review; starting from Phase 1/2 in 2026 makes 2030-2031 extremely tight. Base rate for a novel modality clearing FDA for a common disease within 5 years of early trials is low, under 15%; this case sits below it due to delivery, durability…

Answer

Qwen (Alibaba): 14% — Verve's VERVE-101 for heterozygous familial hypercholesterolemia is the closest candidate, but HeFH is rare, not common CVD. Verve's VERVE-101 targets HeFH (~1 in 250), which is a rare genetic condition, not 'common cardiovascular disease' like atherosclerotic CVD broadly. Base rate for first-in-class in vivo CRISPR approvals is near zero; no such therapy has received FDA approval as of Oct 2026, and typical Phase 2→approval timelines run… The question specifies 'common' CVD, which would require trials in polygenic or broad-population settings—no such program is in late-stage trials today, making approval…

The US FDA approves an in vivo CRISPR-based gene editing therapy for common cardiovascular disease before 2030.

What each one said

The US FDA approves an in vivo CRISPR-based gene editing therapy for common cardiovascular disease before 2030.

A fully bioengineered, lab-grown human solid organ is successfully transplanted into a human patient before 2031.

The FDA suspends or revokes approval of an approved gene-editing therapy due to off-target side effects before 2028.

The FDA approves a therapeutic drug with an explicit indication to slow or reverse human biological aging before 2031.

A fully lab-grown solid human organ is successfully transplanted into a human patient before 2032.